Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpiPrecise

Financiado

Cerrado

Epigenetic profiling of menstrual blood for precision cancer detection and preve...

Epigenetic profiling of menstrual blood for precision cancer detection and prevention Cancer has overtaken cardiovascular disease as the number one cause of mortality in high income countries, cancer incidence is increasing across the globe. Morbidity and mortality from women’s cancers, particularly breast, ovarian... ver más

30/09/2025

UIBK

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAET INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-26

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UIBK

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EPI-FEM-CARE EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE 8M€ Cerrado

RESPONSIFY Genome based biomarkers leading to validated molecular diagn... 8M€ Cerrado

EpiDetect Detecting epigenetic biomarkers in the blood for non-invasiv... 2M€ Cerrado

EPICHECK Detection of Various Cancer Types for Screening and Diagnosi... 71K€ Cerrado

EPIDIACAN Development of sensitive methodologies for exploitation of e... 4M€ Cerrado

FORECEE Female cancer prediction using cervical omics to individuali... 8M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2024-03-26
Fecha Fin: 2025-09-30

Líder del proyecto

UNIVERSITAET INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer has overtaken cardiovascular disease as the number one cause of mortality in high income countries, cancer incidence is increasing across the globe. Morbidity and mortality from women’s cancers, particularly breast, ovarian, and endometrial cancers, follow or exceed these general trends in cancer incidence. Tackling this growing cancer burden requires a multifactorial approach including understanding the fundamental drivers of cancer development; improving methods for detecting earlier those forms of cancer with the worst prognosis; predicting a person’s risk of developing cancer; and identifying appropriate targets for preventing cancer. Indeed, one of the biggest obstacles in identifying tailored cancer prevention strategies is a lack of surrogate readout markers reflecting and integrating an individual’s response to the cancer-initiating and cancer-promoting factors that they are exposed to during their lifetime. Our research delivers novel epigenetic tests relating to each of these key areas with an emphasis on women’s cancers and those who are at an increase risk for cancer due to their underlying genetics, such as women with BRCA1 or BRCA2 mutations and women with Lynch Syndrome. Central to the discovery and development of the epigenetic tests is a cellular deconvolution algorithm that is used to calculate the proportions of cell types within complex, mixed samples such as cervical swabs. In order to broaden the clinical utility of the tests and explore new applications, refinement and expansion of this cellular deconvolution algorithm is now required. The expansion will include cell types in menstrual blood, which is an important and understudied clinical sample type. The EpiPrecise project will deliver this refined and expanded algorithm and apply it to a test case in an area of high unmet clinical need. The refined algorithm will then be applied across the research portfolio and shared.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores